Seres Therapeutics, Inc.
8-K
March 12, 2026
Key Highlights
- Achieved $5.7 million net income from continuing operations in 2025, a significa...
- Strategic focus on promising inflammatory and immunology programs: SER-603 (IBD)...
- Aggressive cost management led to substantial reductions in R&D ($15.5M) and G&A...
Read Analysis
🤖 AI Generated